News

CEO, Anders Hultman, Commenting on FDA delay due to Covid-19

Jan 20, 2021

This weekend the US Food and Drug Administration (FDA) has informed that the impact of the COVID-19 pandemic and the reallocation of staff is leading to an even greater prolonged timeline for reviews of submissions. Anders Hultman, CEO of AroCell, commenting the FDA delay in an interview with Redeye.

Thesis projects at IDL Diagnostics.

We are pleased to recognize four outstanding students who have recently completed their thesis projects with us at IDL Diagnostics. The projects started in January 2025. Putri Rezqita and Yu Shi from Karolinska Institutet contributed their deep knowledge in health and...

read more

EAU 2025

We attended the European Association of Urology #EAU25 in Madrid last weekend. Many valuable insights and great discussion with urologists from all over the world on the latest urology practice and how our products can contribute in improving cancer care. #EAU25 is...

read more